Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model

The successive emergence of SARS-CoV-2 Omicron variants has completely changed the modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that only Sotrovimab has maintained partial activity against BQ.1.1 and XBB.1. In the present study, we used the hamster model...

Descripción completa

Detalles Bibliográficos
Autores principales: Driouich, Jean-Sélim, Bernadin, Ornéllie, Touret, Franck, de Lamballerie, Xavier, Nougairède, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191698/
https://www.ncbi.nlm.nih.gov/pubmed/37207822
http://dx.doi.org/10.1016/j.antiviral.2023.105638
Descripción
Sumario:The successive emergence of SARS-CoV-2 Omicron variants has completely changed the modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that only Sotrovimab has maintained partial activity against BQ.1.1 and XBB.1. In the present study, we used the hamster model to determine whether Sotrovimab retains antiviral activity against these Omicron variants in vivo. Our results show that at exposures consistent with those observed in humans, Sotrovimab remains active against BQ.1.1 and XBB.1, although for BQ.1.1 the efficacy is lower than that observed against the first globally dominant Omicron sublineages BA.1 and BA.2.

Ejemplares similares